History & Establishment

Helping People Lead Happier, Healthier Lives
Taisho's mission is to create and offer superior pharmaceuticals and health-related products as well as health-care-relate information and services that contribute to the enrichment of people's lives by improving health in socially responsible ways. The amount and variety of health information people require are growing along with the greater responsibility people are taking for the maintenance and improvement of their own health. As this way of thinking becomes more prevalent, Taisho believes that, in respect for people's right to know (full information), the right of self-protection (both personal and family), and the right to choose (products and services), it must conduct business form the consumer's perspective, and with a long-term view.

As the foundation of all its corporate activities, Taisho recognizes that now, more than ever, it is following in the tradition of shinsho (gentlemanship in business in accordance with high social ethics), a phrase often mentioned by the Company's first honorary chairman, the late Shokichi Uehara. Keeping the root of its business constantly in mind, and with an earnest desire to work for the consumer, it is Taisho's intention to adhere strictly to its philosophy, and to strive to contribute to all fields related to health.

Growth Strategy
Backed by 90 years of operations, Taisho is a leading company in the self-medication market in Japan. We are making every effort to release new high-value-added products in tune with changing consumer needs, strengthen and foster our brand names, and develop new markets, such as the specified health food market.

In the prescription pharmaceuticals field, Taisho is making concerted efforts o create highly innovative drugs for the global market through its own R&D and in tie-ups with other companies. Recently, Taisho entered a capital and business tie-up with Toyama Chemical Co., Ltd., which has a strong presence and unique drug development technologies in the infectious disease fields, and through this partnership, the Company aims to strengthen its prescription pharmaceutical business. At the same time, Taisho's R&D activities are entering a "bring-up era", where for instance a number of new drug candidates are entering the clinical development stage. Taisho is also bolstering its sales structure so as to fully deploy these new medications on the front line of medicine.